Neoadjuvant chemotherapy (NAC) is offered before surgery, as part of the standard of care, to patients with locally advanced HR+/HER2− BC, early HER2+ BC, or triple-negative BC (TNBC) [4]. This evidence concerns the gene ERBB2 and breast cancer.